靶向蛋白質分解的全球市場（2023-2030）：按用途、技術（PROTAC、LYTAC）、治療領域和適應症分類的規模、佔有率、成長分析和預測

預測期內，全球靶向蛋白質分解市場規模將以 10.2% 的年複合成長率成長，從 2021 年的 1.0331 億美元和 2022 年的 1.1385 億美元成長到 2030 年的 2.4761 億美元，預計將成長到

靶向蛋白水解是一種相對較新的藥物開發策略，由於它使用微小化合物來特異性破壞致病蛋白質，因此越來越受歡迎。據說這種方法在藥物開發方面比傳統方法具有許多優勢。其優點包括獨特的作用方式、聯合治療潛力、廣泛的適用性、改進的選擇性和高耐久性。

對許多疾病更有效的治療方法的需求不斷成長，是目標蛋白質分解市場的促進因素之一。由於它們對患者健康和生活品質具有重大影響，因此對能夠解決癌症、遺傳異常和自身免疫性疾病等疾病根本原因的藥物的需求不斷成長。分解目標蛋白以優先考慮致病蛋白可能會帶來更有效且副作用更少的治療方法。這種策略使得製造能夠選擇性攻擊病原體蛋白質同時保護健康細胞和組織的藥物成為可能。

對口服藥物開發的日益關注是靶向蛋白水解市場的主要發展之一。對方便、合規和患者友好的藥物日益成長的需求正在推動這一發展。與注射和靜脈注射等其他給藥方法相比，口服藥物具有顯著的優勢，因為它們可以方便地在家中服用，不需要患者前往醫院或診所接受治療。多家製藥公司投入巨資研發可分解目標蛋白質的口服藥物，從而生產出可以穿過消化系統到達體內目標器官的藥物。

在本報告中，我們研究了全球靶向蛋白質分解市場，並提供了市場概述、市場各種影響因素分析、技術和創新趨勢、法律和監管環境、市場規模趨勢和預測以及細分細分市場和區域，總結了主要公司的細分、競爭格局、概況等。

目錄

執行摘要

調查方法

母公司市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務

關鍵市場洞察

• 技術分析
• 價格分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 知識產權分析
• 貿易分析
• 啟動分析
• 原料分析
• 創新矩陣
• 管道產品分析
• 宏觀經濟指標
• 主要投資分析
• 關鍵成功因素
• 競爭程度

市場動態及預測

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 監管狀況
• 波特的分析
• Skyquest 對未來顛覆的特別見解

全球目標蛋白分解市場（按用途）

• 市場概況
• 小分子藥物發現
• 蛋白質發現
• 研究
• 其他

全球目標蛋白分解市場（按技術）

• 市場概況
• PROTACs
• LYTACs
• SNIPERs
• 分子膠
• 其他

全球目標蛋白質分解市場：按治療領域

• 市場概況
• 瘤
• 免疫
• 遺傳性疾病/其他

全球目標蛋白分解市場：按適應症分類

• 市場概況
• 乳腺癌
• 肺癌
• 白血病
• 實體瘤/其他

全球目標蛋白質分解市場（按地區）

• 市場概況
• 北美
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東/非洲

競爭格局

• 前5名企業對比
• 主要企業市場定位
• 各大公司的招聘策略
• 關鍵成功策略
• 近期市場活動
• 主要參與者的市場佔有率

主要公司簡介

• Arvinas, Inc.
• C4 Therapeutics
• Kymera Therapeutics
• Nurix Therapeutics
• Dewpoint Therapeutics
• PROTACs Therapeutics
• Amgen Inc.
• AstraZeneca
• Bayer AG
• Celgene Corporation
• Genentech, Inc.
• Gilead Sciences, Inc.
• Novartis AG
• Sanofi SA
• Takeda Pharmaceutical Company Limited.

Global Targeted Protein Degradation Market size was valued at USD 103.31 million in 2021 and is poised to grow from USD 113.85 million in 2022 to USD 247.61 million by 2030, growing at a CAGR of 10.2% in the forecast period (2023-2030).

Since it is a relatively recent strategy for medication development and uses tiny compounds to specifically destroy disease-causing proteins, targeted protein degradation is growing in popularity. This method is said to provide a number of benefits over more conventional approaches to drug development. These benefits include unique method of action, potential for combination therapy, broad applicability, improved selectivity, and higher durability. Top-down and bottom-up approaches were used to estimate and validate the size of Targeted Protein Degradation and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

Applications, technologies, therapeutic areas, indications, and geographical regions are used to segment the global market for targeted protein degradation. The market is divided into Small Molecule Drug Discovery, Protein Discovery, Research Applications, and Other End Use Applications. The market has been divided into PROTACs (Proteolysis-Targeting Chimeras), LYTACs (Lysosome-Targeting Chimeras), SNIPERs (Specific and Non-genetic IAP-dependent Protein ERasers), molecular glues, and other categories based on technology. The market is divided into oncology, immunology, genetic disorders, and other diseases based on therapeutic area. According to preliminary data, the market is divided into categories for solid tumors, leukemia, breast cancer, and lung cancer. North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America are the different geographic segments of the market.

Driver

Increasing Demand for Effective Cancer Treatment to Boost Market Growth

The growing demand for more efficient treatments for a number of disorders is one of the reasons propelling the market for targeted protein degradation. There is a rising demand for medicines that can address the underlying causes of diseases like cancer, genetic abnormalities, and autoimmune diseases because they have a substantial influence on patients' health and quality of life. The potential for preferentially focusing on disease-causing proteins through targeted protein breakdown could lead to more effective treatments with fewer adverse effects. This strategy makes it possible to create medications that selectively attack the pathogen-causing proteins while protecting healthy cells and tissues.

Restraints

Complexity of Targeted Protein Degradation to Hinder Market Growth

The complexity of this industry is one of the main obstacles facing the targeted protein degradation market. This strategy necessitates a thorough knowledge of the structure and purpose of proteins in addition to sophisticated skills in drug research and design. This technique can make it difficult and time-consuming to develop novel therapeutics, which could impede the field's advancement. Developing medications that can selectively degrade particular proteins within cells is a relatively new and complicated field known as targeted protein degradation. These medications are made to benefit from the cell's built-in machinery for protein breakdown, which enables them to specifically target disease-causing proteins while sparing healthy cells.

Market Trend

The increased focus on oral medication development is one of the market's major developments in targeted protein degradation. The rising need for more patient-friendly medicines that provide better convenience and compliance is what is driving this development. Because they may be conveniently administered at home and don't require patients to travel to hospitals or clinics for treatment, oral medications offer a substantial benefit over other drug delivery methods like injections and infusions. Several pharmaceutical companies are making significant investments in the research and development of oral medications for targeted protein breakdown to counter this tendency. Drugs that can make it past the digestive system and into the body's target organs are being developed.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Targeted Protein Degradation Market by Application

• Market Overview
• Small Molecule drug discovery
• protein discovery
• research applications
• and others

Global Targeted Protein Degradation Market by Technology

• Market Overview
• PROTACs (Proteolysis-Targeting Chimeras)
• LYTACs (Lysosome-Targeting Chimeras)
• and SNIPERs (Specific and Non-genetic IAP-dependent Protein ERasers)
• Molecular glues
• and others

Global Targeted Protein Degradation Market by Therapeutic area

• Market Overview
• Oncology
• immunology
• genetic disorder and other diseases

Global Targeted Protein Degradation Market by Indication

• Market Overview
• Breast cancer
• lung cancer
• leukemia
• solid tumors and others

Global Targeted Protein Degradation Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Arvinas, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C4 Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kymera Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nurix Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dewpoint Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PROTACs Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments